Federal grant · project grant (b)
Noninvasive Sleep Enhancement and Behavior Monitoring Technologies for Alzheimer's Model Mice - the Aims of This Project Are to Develop New Technologies to Identify and Track Sleep and Wake Abnormalities Present in Mouse Models of Alzheimer’s Disease (ad), as Well as to Test a Sleep Enhancement Technology for Applications in Ad Animal Research. Signal Solutions, LLC, Has Previously Developed and Commercialized a Piezoelectric Based System for Noninvasive, High-throughput Sleep and Wake Monitoring of Rodents. Automated Scoring of Sleep and Wake Allows for Simultaneous Recordings of Many Animals Over Longer Periods, With Little Burden on the Researcher, Rivalling Eeg/emg Methods That Are More Complicated and Expensive to Perform. Behavioral Changes in Sleep and Wake Can Precede Memory Loss in the Progression of Alzheimer’s Disease (ad). Clinical Studies Suggest Sleep Disturbances Are Exhibited in a High Percentage of Ad Patients. Animal Models of Ad Also Display Sleep Disturbances and Some Models Show Changes in Wake Behaviors Before the Molecular Hallmarks and Memory Problems Appear, as Clearly Occurs in Human Ad. in the Treatment of Ad, a Potential Therapeutic Target Is Preventing the Aggregation of Pathogenic Forms of Amyloid-beta (a-beta) and Tau. Waste Clearance in the Brain Has Been Shown to Be Increased With Increased Sleep, Including Clearance of A-beta. Recently, Non-pharmacological Approaches Using Mechanical Devices for Rocking Have Shown Promise for Sleep Enhancement, Which Could Be Applied to Ad Research. the Specific Aims of This Project Are to 1) Develop Advanced Sleep/wake Tracking Technology: Add a New Multipoint Touch Sensor to Our Current Piezoelectric Technology That Together Will Identify Specific Behaviors Associated With Ad Progression, Tested With Ad Mouse Model 3XTG. 2) Develop Sleep Enhancement Technology: Modify Our Current Mouseqwake Sleep-disruption System for Mechanical Sleep-enhancement, With Companion Sleep and Wake Tracking Capabilities. Anticipated Outcomes: the Envisioned Product Is a Home Cage Sensor and Software That Will Allow Researchers to Accurately Measure Changes in Sleep and Wake During Long-term Ad Disease Progression, as Well as Track Subtle Changes in Behavior in Ad Model Mice. This System Will Minimize the Amount of Work, Time Testing Behaviors, and Time for Analyzing the Videos or Electrophysiology That Is Currently a Major Bottleneck. an Expanded Mouseqwake System Will Provide a Tool for Sleep Manipulation of Both Sleep Enhancement and Disruption as Well as Simultaneous Sleep/wake and Behavioral Recording. If Successful, a Phase Ii Investigation Will Involve Large Scale Studies of Multiple Ad Rodent Models, and Continue Iterative Improvements to Both Hardware and Software Developed in Phase I.
Committed
$287,084
Paid out
$241.0K
84%
Committed, not yet paid
$46.1K
16%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.